Cat. No：GM-C28267
Product：H_EGFR WT BAF3 Cell Line
Cat. No：GM-C28267
Product：H_EGFR WT BAF3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+10 ng/mL EGF+0.25 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase family (TK). It is widely distributed on the surfaces of mammalian fibroblasts, epithelial cells, and other cells. The EGFR signaling pathway plays a crucial role in processes such as cell proliferation and differentiation. Mutations in EGFR lead to continuous activation of the signaling pathway without ligand binding, causing abnormal cell proliferation. EGFR mutations have been identified in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKIs) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and cetuximab. BA/F3 cells are IL-3-dependent pro-B cells, and some protein kinases can replace IL-3 to support Ba/F3 cell growth dependency. This characteristic can be used in the study of kinase inhibitors by counteracting this effect.
Cat. No：GM-C28267
Product：H_EGFR WT BAF3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+10 ng/mL EGF+0.25 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase family (TK). It is widely distributed on the surfaces of mammalian fibroblasts, epithelial cells, and other cells. The EGFR signaling pathway plays a crucial role in processes such as cell proliferation and differentiation. Mutations in EGFR lead to continuous activation of the signaling pathway without ligand binding, causing abnormal cell proliferation. EGFR mutations have been identified in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKIs) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and cetuximab. BA/F3 cells are IL-3-dependent pro-B cells, and some protein kinases can replace IL-3 to support Ba/F3 cell growth dependency. This characteristic can be used in the study of kinase inhibitors by counteracting this effect.
